RoslinCT is a leading global CDMO focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. The company has achieved significant milestones, including being among the first in the world to produce clinical-grade hPSCs and supporting the development and future commercialization of cell therapies based on a range of cell types with an advanced program utilizing CRISPR-edited stem cell-based therapy.
Equipped with 22 purpose-built cGMP processing suites in Edinburgh and Boston, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide.